Pushing the limits of targeted therapy in chronic myeloid leukaemia

被引：250

作者：

O'Hare, Thomas ^{[1
]}

Zabriskie, Matthew S. ^{[1
]}

Eiring, Anna M. ^{[1
]}

Deininger, Michael W. ^{[1
]}

机构：

[1] Univ Utah, Div Hematol & Hematol Malignancies, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

来源：

NATURE REVIEWS CANCER | 2012年 / 12卷 / 08期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; KINASE DOMAIN MUTATIONS; DIAGNOSED CHRONIC-PHASE; BCR-ABL1; LYMPHOBLASTIC-LEUKEMIA; COMPLETE MOLECULAR REMISSION; PATIENTS RECEIVING IMATINIB; CHROMOSOME-POSITIVE CELLS; BCR-ABL INHIBITORS; STEM-CELLS; TYROSINE KINASE;

D O I：

10.1038/nrc3317

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.

引用

页码：513 / 526

页数：14

共 167 条

[71] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[72] MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors [J].

Huntly, BJP ;

Shigematsu, H ;

Deguchi, K ;

Lee, BH ;

Mizuno, S ;

Duclos, N ;

Rowan, R ;

Amaral, S ;

Curley, D ;

Williams, IR ;

Akashi, K ;

Gilliland, DG .

CANCER CELL, 2004, 6 (06) :587-596

[73] BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia [J].

Hurtz, Christian ;

Hatzi, Katerina ;

Cerchietti, Leandro ;

Braig, Melanie ;

Park, Eugene ;

Kim, Yong-mi ;

Herzog, Sebastian ;

Ramezani-Rad, Parham ;

Jumaa, Hassan ;

Mueller, Martin C. ;

Hofmann, Wolf-Karsten ;

Hochhaus, Andreas ;

Ye, B. Hilda ;

Agarwal, Anupriya ;

Druker, Brian J. ;

Shah, Neil P. ;

Melnick, Ari M. ;

Mueschen, Markus .

JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (11) :2163-2174

[74] Targeting hedgehog in hematologic malignancy [J].

Irvine, David A. ;

Copland, Mhairi .

BLOOD, 2012, 119 (10) :2196-2204

[75] PML targeting eradicates quiescent leukaemia-initiating cells [J].

Ito, Keisuke ;

Bernardi, Rosa ;

Morotti, Alessandro ;

Matsuoka, Sahoko ;

Saglio, Giuseppe ;

Ikeda, Yasuo ;

Rosenblatt, Jacalyn ;

Avigan, David E. ;

Teruya-Feldstein, Julie ;

Pandolfi, Pier Paolo .

NATURE, 2008, 453 (7198) :1072-U4

[76] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

Jones, Dan ;

Breeden, Megan ;

Garcia-Manero, Guillermo ;

O'Brien, Susan ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Cortes, Jorge .

BLOOD, 2008, 112 (01) :53-55

[77] The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Shan, Jenny ;

Quintas-Cardama, Alfonso ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Rios, Mary Beth ;

Cortes, Jorge .

BLOOD, 2011, 118 (17) :4541-4546

[78] Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Shan, Jenny ;

Garcia-Manero, Guillermo ;

Wierda, William ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Rios, Mary Beth ;

Cortes, Jorge .

BLOOD, 2011, 117 (06) :1822-1827

[79] Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? [J].

Jabbour, Elias ;

Cortes, Jorge E. ;

Kantarjian, Hagop M. .

MAYO CLINIC PROCEEDINGS, 2009, 84 (02) :161-169

[80] Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay [J].

Jahnke, Wolfgang ;

Grotzfeld, Robert M. ;

Pelle, Xavier ;

Strauss, Andre ;

Fendrich, Gabriele ;

Cowan-Jacob, Sandra W. ;

Cotesta, Simona ;

Fabbro, Doriano ;

Furet, Pascal ;

Mestan, Juergen ;

Marzinzik, Andreas L. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2010, 132 (20) :7043-7048

← 3 4 5 6 7 8 9 10 11 12 →